Johnson & Johnson (JNJ) Stock Analysis
Johnson & Johnson Dividend
The Johnson & Johnson (JNJ) dividend has been paid continuously since 1963 and increased for 54 consecutive years; qualifying the company as a Dividend King, Dividend Aristocrat, and Dividend Champion.
Current Dividend: $3.36
Dividend Yield: 2.5%
Cash Dividend Payout Ratio: 53%
Market Capitalization: $364 B
Enterprise Value 355 B
Industry: Drug Manufacturers – Major
Johnson & Johnson is an investment holding company involved in the research and development, manufacture and sale of pharmaceuticals, hygienic products, and surgical equipment. The company operates with a decentralized management philosophy and operates three business divisions: Consumer, Pharmaceutical and Medical Devices, and Diagnostics.
The Pharmaceutical division (40% of revenues) includes products in the anti-infective, antipsychotic, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, neurology, oncology, pain management, thrombosis and vaccines.
The Medical Devices and Diagnostics division (40% of revenues) is the most comprehensive in the world. This division distributes quality products to wholesalers, hospitals, physicians, nurses, clinics, and retailers.
The Consumer division (20% of revenues) boasts well known brands such as Johnson’s Baby line of products, Aveeno, Clean & Clear, Neutrogena, Listerine, Reach, Band-Aid, Neosporin, Carefree Pantiliners, O.B. Tampons, StayFree sanitary protection products, Splenda No Calorie Sweetener, Tylenol, Sudafed, Zyrtec, Motrin IB, Visine, and Pepcid AC.
Johnson & Johnson has achieved 32 consecutive years of adjusted earning increases and 54 consecutive years of dividend increases. This is a phenomenal record of growth and consistency.
Johnson & Johnson is one of the most trusted brands in the world. It it one of the most consistent earnings grower in history. The 3 healthcare segments provide diversity and unparalleled breadth of quality products for the healthcare industry. Their research pipeline is producing next generation products. In addition, the company has a sales and distribution network that provides JNJ protection from competitors (moat).
Morningstar reports: “We believe Johnson & Johnson carries one of the widest moats in the healthcare sector, supported by intellectual property in the drug group, switching costs in the device segment, and strong brand power from the consumer group.”
Such a gigantic organization requires attention to quality and details to operations that are easily forgotten in a large company. To keep competitive advantages JNJ has to stay focused on the things that have made them the best.
Litigation surrounding several J&J products have the potential to blemish the company’s stellar reputation and cost billions of dollars. This is part of the price a company pays for having so many products.
Developed nations have populations whose average age is increasing rapidly. Older people consume 7 times as much healthcare as young people. In addition, the growing global middle-class will be consuming an increasing amounts of healthcare.
These trends are a huge positive for companies such as JNJ that are positioned to provide access to quality healthcare products and meet the needs of these growing populations.
The largest threat to the healthcare industry is the uncertainty tied to increased scrutiny from consumers and government. Plans for more government run healthcare and regulation make it more difficult to make long term investments, increase the risk of higher litigation costs, and possibly decrease profit margins.
A reduction in pricing power can be expected due to the changing environment. Pharmacy Benefit Managers and government are each putting public and private pressure on reducing profit margins.
Dividend Analyzer Checklist
(updated July 2017)
Dividend Safety Score (22/33 points)
Dividend Per Share (ttm): $3.20
Dividend Payout Ratio (ttm): 53%
Dividend Per Share (10 Year Growth): 8%
Cash From Operations (CFO) Per Share (ttm): $7.02
CFO Dividend Coverage (CFO / DPS): 2.2 (2/6 points)
Free Cash Flow (FCF) Per Share (ttm): $5.89
FCF Dividend Coverage (FCF / DPS): 1.8 (4/6 points)
Net Financial Debt: $ -6973 M
Total Assets: $144918 M
Net Financial Debt / Total Assets: -5% (11/12 points)
Net Financial Debt to EBITDA (ttm): 111%
Total Liabilities to Assets Ratio (Qtr.): 51%
Piotroski Score (1-9) (TTM): (5/9 points)
Profitability & Growth Score (14/33 points)
Revenue (10 Year Growth) *CAGR > 4.14%: 3.0% (0/4 points)
EPS Basic Cont. Operations (10 Year Growth) CAGR > 4.14%: 4.9% (4/4 points)
Cash From Operations (10 Year Growth) CAGR > 4.14%: 2.8% (0/6 points)
Operating Earnings Yield (ttm): 5.7% (2/7 points)
Net Income (ttm): $16505 M
Gross Profit (ttm): $50432 M
Total Assets: $144918 M
Gross Profitability Ratio = GP / Total Assets: 34.8% (8/12 points)
Cash Return On Invested Capital (CROIC)(tttm): 17%
Return on Invested Capital (ROIC): 17%
Return on Invested Capital (ROIC) (5 Year Median): 17%
Return on Invested Capital (ROIC) (10 Year Median): 17%
Valuation Score (14/34 points)
Free Cash Flow Yield (ttm): 4.4% (5/9 points)
EV to EBIT (ttm): 17.1 (4/9 points)
EV to EBITDA (ttm): 14.5 (3/9 points)
PE10: 29.1 (2/7 points)
Price to Sales Ratio (ttm): 5.2
Price to Book Value (ttm): 5.2
Price to Earnings Ratio (P/E) (ttm): 22.7
TOTAL POINTS – (50/100) (50 is an average score)
Stay Updated All the Time!
- Monthly Stock Rankings and Dividend Safety, Profitability & Growth, & Valuation Scores for all 250+ DVB Stocks - Dividend Value Builder Full Membership => $99/year (Analyzer & Portfolio Newsletters)
(updated July 2017)
Type of Investor / Recommendation
Large Diversified Dividend Portfolios / Can Be Considered
Looking For Exposure to Healthcare Sector / Can Be Considered
Deep Value Investors / Avoid
Johnson & Johnson (JNJ) is ranked #101 (out of 251) overall and #8 (out of 16) in the Healthcare sector by the Dividend Analyzer.
Johnson & Johnson is one the greatest public companies ever. Consistent earnings, pristine balance sheet, consistent cash flow, and steady profitability make JNJ a first rate company. However these facts are reflected in the price. Try to buy it on dips.
Portfolio Position Disclosures:
DVB Foundation Portfolio: Long
DVB Dividend Growth: None
DVB High Income: None
Arbor Asset Allocation Model Portfolio (AAAMP): None
Discover, Evaluate, and Compare Dividend Stocks
Dividend Analyzer Newsletter: Analyze Dividend Safety, Profitability & Growth, and Valuation without emotional bias (All DVB Stocks by Total Score and Sector). DVB Portfolio Newsletter => Three DVB Portfolios: Foundation Portfolio, Dividend Growth Portfolio, and High Income Portfolio. Get BOTH Dividend Value Builder Newsletters for $99/year. Free 10-Day Trial. You take NO risk. Start today!